Loading…
Lobbying Spend
—
Filings
17
Firms Hired
1
Active Period
2022–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
2024 · fourth_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to coding, coverage, and reimbursement for biology-guided radiotherapy including H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1691
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
2024 · fourth_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to coding, coverage, and reimbursement for biology-guided radiotherapy, including H.R.1691, The Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to appropriate reimbursement for radiopharmaceuticals.
Client expense: — · Firm income: $60,000
Matched citations: H.R.1691
Facilitating Innovative Nuclear Diagnostics Act of 2023
2024 · third_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to coding, coverage, and reimbursement for biology-guided radiotherapy, including H.R. 1199/S.1544, Facilitating Innovative Nuclear Diagnostics (FIND) Act and H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1199
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
2024 · third_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to coding, coverage, and reimbursement for biology-guided radiotherapy, including H.R.1691, The Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to appropriate reimbursement for radiopharmaceuticals.
Client expense: — · Firm income: $60,000
Matched citations: H.R.1691
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
2024 · third_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to coding, coverage, and reimbursement for biology-guided radiotherapy, including H.R. 1199/S.1544, Facilitating Innovative Nuclear Diagnostics (FIND) Act and H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1691
Facilitating Innovative Nuclear Diagnostics Act of 2023
2024 · third_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to coding, coverage, and reimbursement for biology-guided radiotherapy, including H.R. 1199/S.1544, Facilitating Innovative Nuclear Diagnostics (FIND) Act and H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Client expense: — · Firm income: $60,000
Matched citations: S.1544
Facilitating Innovative Nuclear Diagnostics Act of 2023
2024 · second_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to coding, coverage, and reimbursement for biology-guided radiotherapy, including H.R. 1199/S.1544, Facilitating Innovative Nuclear Diagnostics (FIND) Act and H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1199
Facilitating Innovative Nuclear Diagnostics Act of 2023
2024 · second_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to coding, coverage, and reimbursement for biology-guided radiotherapy, including H.R. 1199/S.1544, Facilitating Innovative Nuclear Diagnostics (FIND) Act and H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1199
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
2024 · second_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to coding, coverage, and reimbursement for biology-guided radiotherapy, including H.R. 1199/S.1544, Facilitating Innovative Nuclear Diagnostics (FIND) Act and H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1691
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
2024 · second_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to coding, coverage, and reimbursement for biology-guided radiotherapy, including H.R. 1199/S.1544, Facilitating Innovative Nuclear Diagnostics (FIND) Act and H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1691
Facilitating Innovative Nuclear Diagnostics Act of 2023
2024 · second_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to coding, coverage, and reimbursement for biology-guided radiotherapy, including H.R. 1199/S.1544, Facilitating Innovative Nuclear Diagnostics (FIND) Act and H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Client expense: — · Firm income: $60,000
Matched citations: S.1544
Facilitating Innovative Nuclear Diagnostics Act of 2023
2024 · second_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to coding, coverage, and reimbursement for biology-guided radiotherapy, including H.R. 1199/S.1544, Facilitating Innovative Nuclear Diagnostics (FIND) Act and H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Client expense: — · Firm income: $60,000
Matched citations: S.1544
Facilitating Innovative Nuclear Diagnostics Act of 2023
2024 · first_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to coding, coverage, and reimbursement for biology-guided radiotherapy, including H.R. 1199/S.1544, Facilitating Innovative Nuclear Diagnostics (FIND) Act and H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1199
Facilitating Innovative Nuclear Diagnostics Act of 2023
2024 · first_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to coding, coverage, and reimbursement for biology-guided radiotherapy, including H.R. 1199/S.1544, Facilitating Innovative Nuclear Diagnostics (FIND) Act and H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1199
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
2024 · first_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to coding, coverage, and reimbursement for biology-guided radiotherapy, including H.R. 1199/S.1544, Facilitating Innovative Nuclear Diagnostics (FIND) Act and H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1691
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
2024 · first_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to coding, coverage, and reimbursement for biology-guided radiotherapy, including H.R. 1199/S.1544, Facilitating Innovative Nuclear Diagnostics (FIND) Act and H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1691
Facilitating Innovative Nuclear Diagnostics Act of 2023
2024 · first_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to coding, coverage, and reimbursement for biology-guided radiotherapy, including H.R. 1199/S.1544, Facilitating Innovative Nuclear Diagnostics (FIND) Act and H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Client expense: — · Firm income: $60,000
Matched citations: S.1544
Facilitating Innovative Nuclear Diagnostics Act of 2023
2024 · first_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to coding, coverage, and reimbursement for biology-guided radiotherapy, including H.R. 1199/S.1544, Facilitating Innovative Nuclear Diagnostics (FIND) Act and H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Client expense: — · Firm income: $60,000
Matched citations: S.1544
Facilitating Innovative Nuclear Diagnostics Act of 2023
2023 · fourth_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to coding, coverage, and reimbursement for biology-guided radiotherapy, including H.R. 1199/S.1544, Facilitating Innovative Nuclear Diagnostics (FIND) Act and H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1199
Facilitating Innovative Nuclear Diagnostics Act of 2023
2023 · fourth_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to coding, coverage, and reimbursement for biology-guided radiotherapy, including H.R. 1199/S.1544, Facilitating Innovative Nuclear Diagnostics (FIND) Act and H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1199
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
2023 · fourth_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to coding, coverage, and reimbursement for biology-guided radiotherapy, including H.R. 1199/S.1544, Facilitating Innovative Nuclear Diagnostics (FIND) Act and H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1691
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
2023 · fourth_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to coding, coverage, and reimbursement for biology-guided radiotherapy, including H.R. 1199/S.1544, Facilitating Innovative Nuclear Diagnostics (FIND) Act and H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1691
Facilitating Innovative Nuclear Diagnostics Act of 2023
2023 · fourth_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to coding, coverage, and reimbursement for biology-guided radiotherapy, including H.R. 1199/S.1544, Facilitating Innovative Nuclear Diagnostics (FIND) Act and H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Client expense: — · Firm income: $60,000
Matched citations: S.1544
Facilitating Innovative Nuclear Diagnostics Act of 2023
2023 · fourth_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to coding, coverage, and reimbursement for biology-guided radiotherapy, including H.R. 1199/S.1544, Facilitating Innovative Nuclear Diagnostics (FIND) Act and H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Client expense: — · Firm income: $60,000
Matched citations: S.1544
Facilitating Innovative Nuclear Diagnostics Act of 2023
2023 · third_quarter · Firm: KOUNTOUPES DENHAM CARR & REID, LLC
Issues related to coding, coverage, and reimbursement for biology-guided radiotherapy, including H.R. 1199/S.1544, Facilitating Innovative Nuclear Diagnostics (FIND) Act and H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1199
Source: Senate LDA